Clinical trial · Observational
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Xpert Bladder Cancer Monitor | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Initial Enrollment
- description
- Initial enrollment of patients with history of bladder cancer
- interventionNames
- Device: Xpert Bladder Cancer Monitor
- label
- Longitudinal Cohort
- description
- Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
- interventionNames
- Device: Xpert Bladder Cancer Monitor
Primary outcomes (2)
- measure
- Comparison to histology for positive or suspicious cystoscopy
- timeFrame
- Baseline = Subject Enrollment
- description
- Comparison to histology for positive or suspicious cystoscopy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Subject is ≥ 40 years of age * Subject has provided documented informed consent as required by the reviewing IRB or EC. Experimental Bill of Rights will be documented for all subjects enrolled in applicable states. * Subject is considered disease positive within 12 months (365 days) of enrollment. * At the time of the enrollment visit, the subject is scheduled for a standard of care cystoscopy which will be completed within 3 days of providing a urine specimen. * Subject has agreed to provide at least 60 mL of voided urine for study purposes at the enrollment visit. * Subject has agreed to provide at least 60 mL of voided urine for study purposes at each subsequent standard of care cystoscopy visit for at least 12 months (365 days) following enrollment if the subject will enter the Longitudinal cohort. * Any subject considered anticipatory positive at the initial visit shall be enrolled into the longitudinal cohort. For each anticipatory positive enrolled into the longitudinal cohort a random disease negative subject shall be enrolled. Exclusion * Subject has been previously enrolled into the study. * Urine specimen to be used for study purposes is from the first morning void. * Subject has had an excision procedure within six weeks (42 days) of enrollment. * The subject is not scheduled for a standard of care cystoscopy visit within 12 months (365 days) following enrollment.
References
Publications (0)
Data not yet available